Clinical trial Recruiting at 1 site Interventional Ages 18 to 100

Pulmonary rehabilitation for adults on high-flow oxygen

Official title: Evaluation of the Effect of Pulmonary Rehabilitation on Patients With High Flow Oxygen Therapy

Run by Chinese PLA General Hospital · NCT04441151 · Data updated 2026-11-12

This test checks whether adding pulmonary rehabilitation helps adults in the ICU who are receiving high-flow humidified oxygen support.

Quick facts

Study typeInterventional
Ages18 Years to 100 Years
SexAll
Enrollment70 (estimated)
SponsorChinese PLA General Hospital
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedMarch 20, 2025
Main results expectedFebruary 1, 2026
Study endsFebruary 1, 2026
Registry record updatedFebruary 9, 2026
Trial IDNCT04441151 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) in the ICU treated with high-flow humidified oxygen who are hemodynamically and neurologically stable, with adequate oxygen saturation and respiratory rate, and without contraindications such as active bleeding or recent fractures.

Probably not a fit

Patients who are hemodynamically unstable, pregnant, actively bleeding, with recent cardio‑cerebrovascular events, unresolved spinal or limb fractures, or uncontrolled seizures are unlikely to be eligible or to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized interventional study enrolled 70 ICU patients receiving high-flow humidified oxygen and assigned them to pulmonary rehabilitation plus routine care or to routine care alone. The intervention arm received a program of pulmonary rehabilitation while the control arm continued standard medical treatment. Measurements at admission and discharge included bedside diaphragm ultrasound, MRC sum for peripheral muscle strength, a 30‑second sit test, the modified Barthel index, Borg dyspnea score, arterial blood gases, and daily vital sign monitoring; use of noninvasive ventilation, intubation, new complications, and time to first out-of-bed were also recorded. The follow-up period and primary endpoint assessment extended to 28 days.

Why it matters

Potential benefit: If successful, adding pulmonary rehabilitation could speed respiratory and functional recovery, reduce the need for noninvasive ventilation or intubation, and lower complication rates.

How similar studies have gone: Prior ICU mobilization and pulmonary rehabilitation programs have shown improved muscle strength, functional status, and reduced ventilator days, although direct evidence specifically in patients on high-flow oxygen is limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* The age is ≥ 18 years old;
* the hemodynamics is stable;
* 50 \< heart rate \< 120 beats / min ;
* 90 \< systolic blood pressure \< 200mmHg ;
* 55 \< mean arterial pressure \< 120mmHg;
* do not increase the dose of pressor drugs for at least 2 hours;
* intracranial pressure is stable and there are no seizures within 24 hours;
* the respiratory state is stable;
* the patient's finger pulse oxygen saturation ≥ 88%;
* 10 \< respiratory frequency \< 35 beats / min.

Exclusion Criteria:

* Pregnancy;
* acute cardio-cerebrovascular events;
* spinal or limb fractures;
* active bleeding.

Where it's running

  • Chinese PLAGH Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.